Cellectis S.A. ADR (CLLS)

Mar 14, 2025, 10:36 AM EDT - 19 days ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 6:07 PM EDT - 20 days ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Mar 7, 2025, 4:30 PM EST - 26 days ago

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Feb 24, 2025, 1:30 AM EST - 5 weeks ago

Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

Dec 12, 2024, 3:08 PM EST - 3 months ago

Cellectis: Poised To Start Answering Questions In 2025

Dec 10, 2024, 4:30 PM EST - 4 months ago

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Nov 5, 2024, 4:30 PM EST - 5 months ago

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Nov 5, 2024, 1:59 PM EST - 5 months ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:30 PM EST - 5 months ago

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Oct 30, 2024, 4:30 PM EDT - 5 months ago

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 22, 2024, 2:00 AM EDT - 5 months ago

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Sep 3, 2024, 4:30 PM EDT - 7 months ago

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Aug 30, 2024, 10:25 AM EDT - 7 months ago

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 26, 2024, 4:30 PM EDT - 7 months ago

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Aug 7, 2024, 2:00 AM EDT - 8 months ago

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Aug 6, 2024, 4:30 PM EDT - 8 months ago

Cellectis Provides Financial Results for the Second Quarter 2024

Aug 1, 2024, 4:30 PM EDT - 8 months ago

FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

Jul 25, 2024, 4:30 PM EDT - 8 months ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Jun 28, 2024, 4:30 PM EDT - 9 months ago

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Jun 20, 2024, 4:30 PM EDT - 10 months ago

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Jun 12, 2024, 4:30 PM EDT - 10 months ago

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Jun 4, 2024, 4:30 PM EDT - 10 months ago

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

May 30, 2024, 2:06 PM EDT - 10 months ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 9:14 AM EDT - 10 months ago

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

May 29, 2024, 4:30 PM EDT - 11 months ago

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

May 28, 2024, 4:30 PM EDT - 11 months ago

Cellectis Reports Financial Results for First Quarter 2024

May 27, 2024, 4:30 PM EDT - 11 months ago

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

May 6, 2024, 2:00 AM EDT - 11 months ago

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

May 2, 2024, 4:30 PM EDT - 11 months ago

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Apr 29, 2024, 4:46 PM EDT - 1 year ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Apr 10, 2024, 4:30 PM EDT - 1 year ago

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Jan 16, 2024, 4:30 PM EST - 1 year ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Dec 22, 2023, 4:30 PM EST - 1 year ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Nov 17, 2023, 4:30 PM EST - 1 year ago

Cellectis' Shareholders Meeting to be Held on December 22, 2023

Nov 15, 2023, 2:30 AM EST - 1 year ago

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Nov 7, 2023, 2:22 PM EST - 1 year ago

Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:30 PM EST - 1 year ago

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Nov 3, 2023, 6:57 PM EDT - 1 year ago

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Nov 2, 2023, 4:30 PM EDT - 1 year ago

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Nov 1, 2023, 4:30 PM EDT - 1 year ago

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Nov 1, 2023, 7:29 AM EDT - 1 year ago

Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

AZN

Nov 1, 2023, 3:17 AM EDT - 1 year ago

AstraZeneca signs drug development deal with biotech Cellectis

AZN

Nov 1, 2023, 3:00 AM EDT - 1 year ago

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Oct 31, 2023, 4:30 PM EDT - 1 year ago

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Oct 24, 2023, 4:30 PM EDT - 1 year ago

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Oct 12, 2023, 4:30 PM EDT - 1 year ago

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Sep 27, 2023, 4:30 PM EDT - 1 year ago

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Aug 7, 2023, 4:30 PM EDT - 1 year ago

Cellectis Provides Full Report for Second Quarter 2023 Financial Results